Best Supplements for Reduced Inflammation
Ranked by research evidence. Compare 128 supplements across 227 papers from the biomedical literature, with effect direction, evidence strength, and dose range for each.
Top picks by evidence
- Moderate evidence9 studies
Across 9 studies, all reported beneficial effects of Lactobacillus acidophilus L-92 on reducing inflammation, with effect sizes ranging from small to moderate. The most robust evidence comes from a large meta-analysis (n=3390) in subjects with type 2 diabetes, showing small beneficial effects on inflammatory markers such as C-reactive protein and tumor necrosis factor alpha. A single small randomized controlled trial in underweight participants reported statistically significant moderate reductions in inflammatory markers (ESR, CRP).
- Moderate evidence9 studies
Across 8 studies, 7 reported beneficial effects of Bifidobacterium plantarum on inflammation, with a predominant moderate effect size. The highest-quality evidence, a meta-analysis in athletes (n=413), showed a significant moderate reduction in TNF-α (ES=-0.59, p=0.001). However, one systematic review in adults with alcoholic liver disease found no significant effect on inflammatory markers, and the remaining studies are narrative or animal-based, limiting the overall human evidence base.
- Moderate evidence8 studies
Across 8 studies, all reported beneficial effects of Lactobacillus salivarius UCC118 on reducing inflammation, with effect sizes ranging from small to moderate. Moderate evidence from a large meta-analysis (n=896) in women with gestational diabetes showed a significant reduction in C-reactive protein. The most commonly studied populations were individuals with metabolic or inflammatory conditions, though dose ranges and study durations were not consistently reported.
128 supplements
- Very lowLactobacillus rhamnosusAcross 13 studies, 13 reported beneficial effects of *Lactobacillus rhamnosus* on reduced inflammation, with a predominant moderate effect size. Only 2 studies reached statistical significance, both in animal models, and the evidence is largely from low-quality studies (in vitro, animal, or narrative reviews) rather than high-quality human RCTs. No consistent dose range or study duration was reported across the available evidence.15 beneficial15 studies
- ModerateLactobacillus acidophilus L-92Across 9 studies, all reported beneficial effects of Lactobacillus acidophilus L-92 on reducing inflammation, with effect sizes ranging from small to moderate. The most robust evidence comes from a large meta-analysis (n=3390) in subjects with type 2 diabetes, showing small beneficial effects on inflammatory markers such as C-reactive protein and tumor necrosis factor alpha. A single small randomized controlled trial in underweight participants reported statistically significant moderate reductions in inflammatory markers (ESR, CRP).9 beneficial9 studies
- ModerateBifidobacterium plantarumAcross 8 studies, 7 reported beneficial effects of Bifidobacterium plantarum on inflammation, with a predominant moderate effect size. The highest-quality evidence, a meta-analysis in athletes (n=413), showed a significant moderate reduction in TNF-α (ES=-0.59, p=0.001). However, one systematic review in adults with alcoholic liver disease found no significant effect on inflammatory markers, and the remaining studies are narrative or animal-based, limiting the overall human evidence base.8 beneficial1 neutral9 studies
- ModerateLactobacillus salivarius UCC118Across 8 studies, all reported beneficial effects of Lactobacillus salivarius UCC118 on reducing inflammation, with effect sizes ranging from small to moderate. Moderate evidence from a large meta-analysis (n=896) in women with gestational diabetes showed a significant reduction in C-reactive protein. The most commonly studied populations were individuals with metabolic or inflammatory conditions, though dose ranges and study durations were not consistently reported.8 beneficial8 studies
- LowLactobacillus brevis SBC8803Across 5 studies, all reported beneficial effects with predominantly moderate effect sizes. The only randomized controlled trial (RCT) found a significant moderate effect on reducing exercise-induced inflammation in healthy adults after 6 weeks of administration. However, the remaining 4 studies are reviews that provide indirect mechanistic support rather than direct clinical evidence from interventions with Lactobacillus brevis SBC8803.8 beneficial8 studies
- LowSaccharomyces cerevisiaeAcross 6 available studies, all report beneficial effects of Saccharomyces cerevisiae on inflammation, with predominantly moderate effect sizes. The strongest evidence comes from a small RCT (n=12) showing significant reductions in microvascular inflammation and irritation scores in healthy adults. Most studies used dried yeast fermentate, though doses and durations are not consistently reported.7 beneficial7 studies
- ModerateVitamin DAcross 5 studies, all 5 reported beneficial effects on reducing inflammation, with 4 of 5 statistically significant. The predominant effect size was small, though one meta-analysis showed a moderate reduction in older adults. Most studies focused on elderly populations or patients with inflammatory arthritis.5 beneficial5 studies
- LowBifidobacterium animalis subsp. lactis BB-12Across 4 studies, all 4 reported beneficial effects on reduced inflammation, with predominantly small effect sizes. No specific dose range, population, or study duration was consistently reported across the included studies.4 beneficial4 studies
- LowLactobacillus amylovorusAcross 4 studies, all reported beneficial effects on inflammation. The strongest evidence comes from a meta-analysis of 25 RCTs showing a small but significant reduction in C-reactive protein (CRP) (-0.99 mg/L). Three additional studies reported moderate beneficial effects but in animal models (sows, lambs) or cell cultures, and their direct relevance to Lactobacillus amylovorus is uncertain. The predominant effect size is mixed (small from the meta-analysis, moderate from the others). No consistent dose range was identified, and study durations were not consistently reported.4 beneficial4 studies
- LowBifidobacterium breve Bb-18Across 4 studies, all reported beneficial effects of Bifidobacterium breve Bb-18 on reducing inflammation, with effect sizes ranging from small to moderate. The evidence primarily comes from a large 2025 meta-analysis in subjects with type 2 diabetes mellitus (n=3390), showing small beneficial effects on inflammatory markers such as high-sensitivity C-reactive protein and tumor necrosis factor alpha. No consistent dose range or study duration was reported across the studies.4 beneficial4 studies
- LowLactobacillus rhamnosus GR-1Across 3 studies, all reported beneficial moderate-sized effects of Lactobacillus rhamnosus GR-1 on reducing inflammation. Two of the three studies reported statistically significant findings. The evidence is derived from in vitro cell line experiments and animal models, with no human clinical trial data available.4 beneficial4 studies
- ModeratePomegranateAcross 3 studies, all reported beneficial effects on inflammation, with two showing moderate effect sizes and one small. The evidence comes from systematic reviews covering oral health, rheumatic conditions, and athletic recovery. No consistent dose or form was reported.3 beneficial3 studies
- LowVitamin EAcross 3 studies, all reported beneficial effects of vitamin E on reducing inflammation, with effect sizes ranging from small to large. The median study duration was 84 days (12 weeks), suggesting effects typically observed at 8-12 weeks. The most studied population was clinical adults (e.g., post-surgery, sarcopenic women, NAFLD patients). · Dose: 335 mg/d3 beneficial3 studies
- LowBifidobacterium lactis Bb-02Across 3 studies, all reported beneficial effects of Bifidobacterium lactis Bb-02 on reducing inflammation, with effect sizes ranging from small to moderate. The highest-quality evidence comes from a large meta-analysis (n=3390) in type 2 diabetes patients, which found reductions in CRP and TNF-α alongside increases in the anti-inflammatory cytokine IL-10. Effects in other populations (gestational diabetes, neurodegenerative diseases) were based on small or qualitative reviews.3 beneficial3 studies
- LowLactobacillus casei PXN 37Across 3 studies, all reported beneficial effects of Lactobacillus casei PXN 37 on reducing inflammation, with moderate effect sizes in 2 studies and a small effect in 1. The evidence draws from meta-analyses in autoimmune and depression populations, but the evidence base is small. Doses and study durations were not consistently reported.3 beneficial3 studies
- Very lowLactobacillus casei rhamnosusAcross 3 studies, all reported beneficial effects on inflammation, with effect sizes ranging from small to moderate. The evidence is preliminary and mostly from review-level analyses, with no statistically significant findings reported. The most studied population includes women with gestational diabetes mellitus and animal models, but dose and duration data are not available.3 beneficial3 studies
- Very lowLactobacillus acidophilus La-14Across 3 studies, all reported beneficial effects of Lactobacillus acidophilus La-14 on reduced inflammation, with moderate effect sizes observed in two studies and a small effect in one. Most evidence comes from studies on women with gestational diabetes mellitus (GDM). The evidence base is very small and no studies reported statistically significant results, so conclusions are preliminary.3 beneficial3 studies